Heart attacks and strokes are among the leading causes of death globally, with millions suffering from cardiovascular diseases (CVD) every year. There are more than seven million people in the UK alone, with about 100,000 patients experiencing heart attacks annually. However, a group of researchers at University College London (UCL) estimate that one 'polypill' taken daily day could eliminate a majority of these cases dramatically lowering death tolls.

The proposed polypill, a combination of a statin and three blood pressure-lowering drugs, has been under study for over two decades. Experts argue that introducing this pill universally for individuals aged 50 and above could be more effective than the current NHS Health Check, which assesses risk factors every five years for those aged between 40 and 74.

Studies have repeatedly proven the effectiveness of the polypill in preventing CVD. A groundbreaking 2019 study in The Lancet found that five years' use of the polypill cut the risk of heart attack and stroke by a third. In addition, previous modelling analyses have estimated that if given universally to people over 55, the polypill might be able to prevent 80% of heart attacks and strokes.

Today, the NHS Health Check follows a risk-based model in which patients are tested for CVD risk factors and treated with drugs accordingly. Yet, as per UCL's study, this system has serious flaws:

Low Uptake: Just 40% of those eligible for the NHS Health Check choose to have it, leaving a considerable number of at-risk patients undiagnosed and untreated.

Ineffective Prediction of Risk: The majority of heart attacks and strokes happen to people at average risk levels, thus making it challenging to identify the need for intervention effectively.

Limited Effectiveness: Even at maximum take-up, the NHS Health Check programme is predicted to have fewer health impacts compared to a polypill initiative applied to the whole population.

Simplicity and Affordability of the Polypill Strategy

One of the big benefits of the polypill is that it is so easy. In contrast to the existing screening-based model, the polypill scheme would not involve complicated medical tests or lengthy risk assessments. Instead, people reaching 50 would just have to fill out a few questions to determine possible side effects before they were prescribed.

Professor Aroon Hingorani of the UCL Institute of Cardiovascular Science, one of the strongest proponents of this scheme, says:

"Finally, the time is now to do much better on prevention. A population approach would prevent a lot more heart attacks and strokes than is done today with a strategy of trying to target a smaller group only."

Aside from the possible health implications, the polypill is also an economic solution. The drugs used are off-patent, thus cheap to produce and distribute. With the vast economic cost of managing CVD-related illnesses, a preventive model could result in substantial cost-saving for the NHS in the future.

The polypill has been proven to be effective by numerous international trials. In 2019, a randomised trial in rural Iran discovered that participants who took the polypill for five years had a 34% reduced risk of having a heart attack or stroke compared to non-participants.

Likewise, modelling research has indicated that even if only 8% of people aged over 50 took up the polypill regimen, it would still be more beneficial to their health than the NHS Health Check programme.

Is This a Case of Over-Medicalisation?

One of the main objections to the polypill strategy is the suggestion that it might result in the unnecessary medicalisation of a significant proportion of the population. But, it is argued, it should be considered as a preventative measure, not as mass medication.

Professor Sir Nicholas Wald of UCL's Institute of Health Informatics explains:

"Instead of being a 'medicalisation' of a significant proportion of the population, a polypill programme is a prevention measure to prevent an individual from becoming a patient."

He compares it with public health measures like water fluoridation or compulsory seatbelts—interventions that have been shown to have a significant impact in reducing public health danger at low individual cost.

With the evidence in favour of the polypill's effectiveness and viability overwhelming, experts are calling on the NHS to act now. It is their belief that substituting the NHS Health Check with a polypill-based prevention program could be the UK government's flagship policy under its pledge to put disease prevention ahead of cure.

As Professor Hingorani points out, "The status quo is not a justifiable option." With CVD still a major cause of death globally, taking a population-wide polypill approach could be a turning point for preventative medicine, potentially saving thousands of lives annually. The question now is whether the NHS will take up this call and establish a policy with the potential to transform the prevention of cardiovascular disease on a national level.

US President Donald Trump has nominated Dr Nicole Saphier to serve as US Surgeon General, making her the third person he has chosen for the position.

Saphier’s nomination comes after Trump withdrew the nomination of Dr Casey Means in April after her confirmation stalled in the Senate. Trump had earlier withdrawn his first nominee, Fox News medical contributor Dr Janette Nesheiwat, following questions over her academic credentials.

Saphier will need to be confirmed by the Senate before she can take up the position. She is appearing before the Senate Health, Education, Labor and Pensions (HELP) Committee on Wednesday for her confirmation hearing.

Who Is Dr Nicole Saphier?

Saphier is the director of breast imaging at Memorial Sloan Kettering Monmouth, according to her profile on the New York-based cancer centre’s website. She earned her medical degree from Ross University School of Medicine in Barbados and completed fellowships at Mayo Clinic, according to the profile.

She is also a former Fox News contributor and has been a public voice on issues including breast cancer prevention, COVID-19 policies, vaccines and chronic disease.

“Dr. Nicole Saphier is an accomplished physician who has practiced radiology at Memorial Sloan-Kettering and has been an outspoken voice on breast cancer prevention, intrusive COVID-19 mandates, the politicization of science, and the federal government’s role in America’s chronic disease epidemic,” White House spokesman Kush Desai said in a statement.

“She has been a powerful asset for President Trump and works tirelessly to deliver on every facet of his MAHA agenda,” Desai added.

Saphier Faces Questions On Vaccines And Public Health

Read More: Meet Heidi Overton: Trump Set to Nominate White House Adviser to Lead FDA

While senators may scrutinise Saphier’s credentials and professional background, she is also expected to face questions about how she would navigate Health Secretary Robert F. Kennedy Jr.’s public-health policies if confirmed.

Vaccination policy is likely to be a major focus. The administration has moved to reconsider aspects of federal vaccine guidance, while measles outbreaks have raised concerns among public-health experts.

Lawmakers from both parties have criticised Kennedy’s positions on vaccines, and senators are expected to question Saphier about whether she would take a stronger stance in support of vaccination if confirmed.

Saphier has questioned the need for every newborn to receive the hepatitis B vaccine at birth, a longstanding recommendation that the Trump administration has also sought to change.

At the same time, she has disagreed with Trump and Kennedy on some health issues. In an interview with The Associated Press last year, she said Trump’s warnings about pregnant women taking Tylenol were oversimplistic and “patronizing.”

Saphier's Social Media And Supplement Business

Also read: Dr. Erica Schwartz Confirmed As CDC’s First Permanent Director In Nearly A Year

Saphier also has a significant social-media presence, with about 147,000 followers on Instagram. Her profile identifies her as the creator of DropRx, a brand of liquid herbal supplements.

According to her financial disclosure and ethics forms, Saphier will divest holdings in a range of companies, including those in the food, soda and pharmaceutical industries.

Her ethics agreement also states that, if confirmed by the Senate, she will resign from DropRx, her dietary and herbal supplement company, and Empower MD, which owns DropRx.

What Will Senators Ask Nicole Saphier?

Vaccination policy is expected to be a major focus of Saphier’s confirmation hearing.

Senators are also expected to question the nominees about the cancellation of government grants and the US opioid crisis.

Saphier is appearing before the HELP Committee alongside Chris Klomp, Trump's nominee for Deputy Secretary of Health and Human Services, and Timothy Westlake, his pick to lead the Substance Abuse and Mental Health Services Administration.

Fiji has declared a national HIV emergency after recent reports and estimates showed that around one in every 60 adults may now be living with HIV.

The estimate has sparked concern as it marks a sharp rise from about one in 167 adults five years ago.

Fiji recorded more than 2,000 new HIV diagnoses in 2025. Health officials have attributed the grim development to unsafe injecting practices, lack of sterile equipment and major gaps in HIV treatment and prevention.

Health Minister Dr Atonio Lalabalavu said the scale and reach of the epidemic required a response that is more effective than existing outbreak measures.

“The findings also show the seriousness of the epidemic and the gaps we must close in prevention, treatment and continuing care. We have acted on that evidence. An outbreak-level response is no longer sufficient. The Ministry of Health cannot meet this challenge alone. It requires coordinated action across Government, alongside communities and our partners.”

Factors Driving Rising HIV Cases In Fiji

Health officials and HIV experts have identified injectable drug use, especially meth, as a major driver of the current surge.

The concern is not methamphetamine abuse itself transmitting HIV. The risk arises when people who inject drugs share needles and syringes to ingest the drugs.

Dr Jason Mitchell, chair of Fiji’s National HIV Outbreak and Cluster Response Taskforce, said, “Fiji is currently navigating the fastest-growing HIV epidemic in the world, and what is driving this epidemic now is risky injecting drug use of people who currently inject methamphetamines.”

He added, “The unavailability of sterile needles and syringes has resulted in people who use drugs sharing needles, syringes and drug-mixing equipment.”

UNAIDS has previously highlighted the scale of the change. It reported that new HIV infections in Fiji had increased tenfold since 2014, while only 36% of people living with HIV were estimated to know their status in 2024 and just 24% were receiving treatment.

Also read: Thailand’s HIV Cases Cross 550,000 In 2026; Over 25,000 Among 15–24s

Growing Treatment Gap

Finding people with HIV is only the first step. They need to remain connected to treatment to contain transmission.

Recent reports found that the proportion of diagnosed people receiving antiretroviral therapy had fallen from more than 98% before 2021 to around 56%.

“We are now finding people faster than we are able to keep them in care,” Mitchell said.

Antiretroviral therapy suppresses HIV in the body and allows people living with HIV to lead long, healthy lives.

When treatment reduces the virus to an undetectable level, people do not sexually transmit HIV, a principle known as U=U, or undetectable equals untransmittable.

Also read: Exclusive With Leading HIV Expert: What's Driving Rising HIV Cases Among India's Youth And How To Prevent It

Fiji Plans Needle Exchange And More PrEP

The government says its response will include expanded HIV testing and treatment, greater access to pre-exposure prophylaxis (PrEP) and the introduction of a formal needle and syringe programme.

It also plans to strengthen its follow-up care system so people diagnosed with HIV remain connected to treatment.

The emergency declaration comes as HIV prevalence among women attending antenatal care has reached around 2%, or about one in 50 pregnant women.

That figure raises the concern of mother-to-child transmission. HIV can be transmitted during pregnancy, childbirth or breastfeeding, but effective treatment and preventive care can dramatically reduce this risk.

Delhi has reported 121 dengue cases so far in September, taking the city’s total this year to 432, according to recent data from the Municipal Corporation of Delhi (MCD).

September has recorded the highest number of dengue cases in a single month so far this year, accounting for more than a fourth of the total cases as the monsoon season continues.

The month has also recorded the highest number of malaria cases so far this year, with no malaria-related deaths reported, according to MCD data.

The Delhi reported 90 dengue cases in August. Malaria cases rose from 17 in July to 53 in August, taking the cumulative malaria tally to 119 by the end of August, according to the MCD.

Highest Dengue Cases

Also read: ICMR Study Shows Pune Dengue Mosquitoes Resistant To Insecticides: What It Means for Public Health

According to the MCD’s weekly vector-borne disease report, the national capital recorded 71 new dengue infections over the past week alone.

West Delhi has reported the highest number of dengue cases this year, with 57 cases, followed by Central Delhi with 54 and Shahdara North with 50.

Delhi had reported 619 dengue cases during the corresponding period in 2025, compared with 709 in 2024, 2,097 in 2023 and 295 in 2022.

Malaria Cases Also Rise

Delhi has recorded 183 malaria cases so far this year, including 64 cases in September, the highest monthly figure reported this year. However, no malaria-related deaths have been reported, the MCD data showed.

The capital has also recorded 24 chikungunya cases so far this year, compared with 46 during the corresponding period in 2025. Two chikungunya cases have been reported in September so far.

Read More: Will India Be Malaria-Free By 2030? 160 Districts Report Zero Cases Over 3 Years; Burden Falls 80% In A Decade

Is Climate Behind Dengue Spread?

Temperature and other environmental conditions can affect mosquito survival, reproduction and biting behaviour, as well as how quickly the dengue virus develops inside the mosquito.

Warmer conditions can create more favourable conditions for dengue transmission and potentially expand the areas where dengue-carrying mosquitoes can survive.

Recently released WHO's Global Public Health Situation Analysis – El Niño 2026 also identified India among countries facing high or very high health risks as El Niño event is on its way to alters weather patterns across South Asia.

El Niño is a periodic warming of surface waters in the central and eastern tropical Pacific Ocean that can disrupt weather patterns around the world.

As per the WHO assessment identified India is at high or very high risk, with most of South Asia, for a drier-than-normal conditions and above-normal heat during August-October.

Such changes in temperature and rainfall can influence mosquito populations and the transmission of vector-borne diseases.

READ: Dengue Is Spreading Beyond Monsoons And Into New Regions Across India, Says Expert

How To Prevent Mosquito Bites

To lower your risk of dengue and other mosquito-borne diseases:

• Wear clothes that cover as much of the body as possible

• Use mosquito nets, ideally treated with insect repellent, when sleeping during the day

• Install window screens

• Use repellents containing DEET, picaridin or IR3535.

• Use mosquito coils and vaporizers.

How To Stop Mosquitoes From Breeding

• Remove places where water can accumulate

• Dispose of solid waste properly

• Cover, empty and clean domestic water-storage containers weekly.

• Remove artificial containers that can hold water.

• Use appropriate insecticides in outdoor water-storage containers.